BMO ARK Genomic Revolution Fund (NEO:ARKG)
Canada · Delayed Price · Currency is CAD | Assets | 4.40M |
| Expense Ratio | 0.96% |
| PE Ratio | n/a |
| Dividend (ttm) | 0.10 |
| Dividend Yield | 0.90% |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +4.71% |
| Volume | 614 |
| Open | 10.74 |
| Previous Close | 11.03 |
| Day's Range | 10.68 - 10.74 |
| 52-Week Low | 8.34 |
| 52-Week High | 14.10 |
| Beta | n/a |
| Holdings | 35 |
| Inception Date | Nov 14, 2022 |
About ARKG
BMO ARK Genomic Revolution Fund is an exchange traded fund launched by BMO Investments Inc. The fund is managed by ARK Investment Management LLC. The fund invests in public equity markets of global region. It invests in stocks of companies operating across disruptive genomic innovation sectors. It invests in growth and value stocks of companies across diversified market capitalization. It employs fundamental analysis to create its portfolio. The fund seeks to benchmark the performance of its portfolio against the MSCI ACWI Health Care Index (C$). BMO ARK Genomic Revolution Fund was formed on November 1, 2022 and is domiciled in Canada.
Performance
ARKG had a total return of 4.71% in the past year, including dividends. Since the fund's inception, the average annual return has been -10.64%.
Top 10 Holdings
60.08% of assets| Name | Symbol | Weight |
|---|---|---|
| CRISPR Therapeutics AG | CRSP | 9.61% |
| Tempus AI, Inc. | TEM | 9.27% |
| Twist Bioscience Corporation | TWST | 7.37% |
| Guardant Health, Inc. | GH | 6.59% |
| Recursion Pharmaceuticals, Inc. | RXRX | 5.56% |
| Natera, Inc. | NTRA | 5.32% |
| Adaptive Biotechnologies Corporation | ADPT | 4.39% |
| Personalis, Inc. | PSNL | 4.37% |
| CareDx, Inc | CDNA | 3.85% |
| Schrödinger, Inc. | SDGR | 3.77% |